Demographics (2)
- AGE - Subject age at consent (phv00534884.v1.p1)
- SEX - Biological sex (phv00534880.v1.p1)
Race and Ethnicity (1)
- RACE - Race (phv00534885.v1.p1)
Other (13)
- ANALYTE_TYPE - Analyte type (phv00534892.v1.p1)
- BODY_SITE - Body site where sample was collected (phv00534891.v1.p1)
- CONSENT - Consent group (phv00534879.v1.p1)
- HISTOLOGY - Lymphoma subtype histology (phv00534886.v1.p1)
- IS_TUMOR - Tumor status (phv00534893.v1.p1)
- RANDOMIZATION_ARM - Randomized study arm (phv00534887.v1.p1)
- SAMPLE_ID - Sample ID (phv00534890.v1.p1)
- SAMPLE_ID - Sample ID (phv00534882.v1.p1)
- STUDY_EVENT - Whether or not subject experienced an event on Study. Events include: no response at week 13, progression, new treatment, or death (phv00534889.v1.p1)
- SUBJECT_ID - DbGaP Subject ID (phv00534883.v1.p1)
- SUBJECT_ID - DbGaP Subject ID (phv00534878.v1.p1)
- SUBJECT_ID - DbGaP Subject ID (phv00534881.v1.p1)
- WEEK13_RESPONSE - Response to treatment at 13 Weeks using Lugano criteria (phv00534888.v1.p1)